摘要
目的 探究穴位贴敷联合脐灸改善肺癌化疗患者癌因性疲乏(CRF)的治疗效果.方法 选取威海市中医院 2022 年 7 月—2023 年 1 月收治的 100 例肺癌患者为受试对象,采用随机数字表法分为对照组与试验组,各 50 例.对照组给予中西医结合基础治疗,试验组在中西医结合基础治疗的同时采用穴位贴敷联合脐灸治疗.比较治疗前与治疗 14 d后两组患者的中医证候评分、CRF情况[癌症疲乏量表(CFS)]、不良反应情况[MD Anderson症状评估(MDASI-TCM)]、生活质量情况(QLQ-LC43)评分.结果 治疗 14 d后,试验组总有效率(94.00%)高于对照组(78.00%,P＜0.05);两组患者中医证候评分、CFS评分、MDASI-TCM评分及QLQ-LC43 评分中的QLQ-C30、QLQ-LC13 评分均较治疗前降低(P＜0.01,P＜0.05),且试验组均低于同一时间对照组(P＜0.01,P＜0.05).结论 穴位贴敷联合脐灸临床疗效显著,可有效缓解肺癌化疗患者CRF,减轻化疗不良反应,且有助于提高患者生活质量.
Abstract
Objective To explore the therapeutic effect of acupoint application combined with navel moxibustion on cancer-related fatigue(CRF)in lung cancer patients undergoing chemotherapy.Methods A total of 100 lung cancer patients admitted to Weihai Traditional Chinese Medicine Hospital from July 2022 to January 2023 were enrolled and randomly divided into a control group and an experimental group,with 50 cases in each group,using a random number table.The control group received basic treatment with integrated traditional Chinese and Western medicine,while the experimental group received acupoint application combined with navel moxibustion therapy in addition to basic treatment with integrated traditional Chinese and Western medicine.The traditional Chinese medicine(TCM)syndrome scores,CRF status(Cancer Fatigue Scale,CFS),adverse reactions(MD Anderson Symptom Assessment,MDASI-TCM),and quality of life(QLQ-LC43)scores of the two groups of patients before and after 14 days of treatment were compared.Results After 14 days of treatment,the total effective rate of the experimental group(94.00%)was higher than that of the control group(78.00%,P<0.05).The TCM syndrome scores,CFS scores,MDASI-TCM scores,and QLQ-C30 and QLQ-LC13 scores in QLQ-LC43 of both groups of patients decreased compared to those before treatment(P<0.01,P<0.05),and the scores of the experimental group were lower than those of the control group at the same time point(P<0.01,P<0.05).Conclusion Acupoint application combined with navel moxibustion has a significant clinical effect,effectively alleviating CRF in lung cancer patients undergoing chemotherapy,reducing adverse reactions to chemotherapy,and helping to improve the quality of life of patients.
基金项目
威海市中医药科技项目(2022)(2022N-13)
NETL
NSTL
万方数据